Logo
x

Search

Subscribe Now

leo pharma

LEO Pharma Reports the Regulatory Submission of Enstilar to the NMPA for Treating Plaque Psoriasis

LEO Pharma Reports the Regulatory Submission of Enstilar to the NMPA for Treating Plaque Psoriasis

  • September 27, 2024
LEO Pharma’s Anzupgo (Delgocitinib) Gains the CHMP’s Positive Opinion to Treat Moderate to Severe Chronic Hand Eczema (CHE)

LEO Pharma’s Anzupgo (Delgocitinib) Gains the CHMP’s Positive Opinion to Treat Moderate to Severe Chronic Hand Eczema (CHE)

  • July 26, 2024
LEO Pharma’s Adbry (tralokinumab-ldrm) Autoinjector Receives the US FDA’s Approval to Treat Moderate-to-Severe Atopic Dermatitis (AD)

LEO Pharma’s Adbry (tralokinumab-ldrm) Autoinjector Receives the US FDA’s Approval to Treat Moderate-to-Severe Atopic Dermatitis (...

  • June 13, 2024
Leo Pharma to Acquire Timber for ~$36M

Leo Pharma to Acquire Timber for ~$36M

  • August 22, 2023
PharmaShots Weekly Snapshots (February 06 - 10, 2023)

PharmaShots Weekly Snapshots (February 06 - 10, 2023)

  • February 10, 2023
LEO Pharma Reports P-III Trial (DELTA 2) Results of Delgocitinib for Chronic Hand Eczema

LEO Pharma Reports P-III Trial (DELTA 2) Results of Delgocitinib for Chronic Hand Eczema

  • February 10, 2023
Image

Incisive News in 3 Shots.

Contact Us

Our Information

Follow Us

Copyright © 2024 PharmaShots - All Rights Reserved.